Dendritic cell immunotherapy for HIV-1 infection using autologous HIV-1 RNA: A randomized, double-blind, placebo-controlled clinical trial

Journal of Acquired Immune Deficiency Syndromes

Volumn 72, Issue 1, 2016, Pages 31-38

  Jacobson, Jeffrey M ^a   Routy, Jean Pierre ^b   Welles, Seth ^a   DeBenedette, Mark ^c   Tcherepanova, Irina ^c   Angel, Jonathan B ^d   Asmuth, David M ^e   Stein, David K ^f   Baril, Jean Guy ^g   McKellar, Mehri ^h   Margolis, David M ⁱ   Trottier, Benoit ^j   Wood, Kenneth ^k   Nicolette, Charles ^d  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c Argos Therapeutics Inc   (United States)

^d UNIVERSITY OF OTTAWA   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g Clinique Medicale du Quartier Latin   (Canada)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^j Clinique Medicale l'Actuel   (Canada)

^k FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

more..

Author keywords

Autologous antigen; Dendritic cell therapy; Functional cure; HIV; Therapeutic immunization

Indexed keywords

AGS 004; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD14 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD45RA ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; D DIMER; DENDRITIC CELL VACCINE; GAG PROTEIN; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NEF PROTEIN; PLACEBO; REV PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS RNA; VPR PROTEIN; GRANZYME; IL2 PROTEIN, HUMAN; NEF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; TUMOR NECROSIS FACTOR; VPR PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; AXILLARY LYMPH NODE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DEMOGRAPHY; DENDRITIC CELL; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; EFFECTOR CELL; FATIGUE; FEMALE; FLOW CYTOMETRY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOASSAY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; MULTICENTER STUDY; NAUSEA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT INTERRUPTION; VIVID DREAM; ADOLESCENT; ADULT; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; GENETICS; HIV INFECTIONS; IMMUNOLOGY; IMMUNOTHERAPY; MIDDLE AGED; PROCEDURES; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DOUBLE-BLIND METHOD; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GRANZYMES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-2; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MALE; MIDDLE AGED; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PLACEBOS; REV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RNA, VIRAL; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; YOUNG ADULT;

EID: 84954509568     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000926     Document Type: Article

References (14)

1. Archin NM, Sung JM, Garrido C, et al. Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol. 2014;12:750-764.
2. Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after viral reactivation. Immunity. 2012;36:491-501.
3. Kutzler MA, Jacobson JM. Treatment interruption as a tool to measure changes in immunologic response to HIV-1. Curr Opin HIV AIDS. 2008; 3:131-135.
4. Jacobson JM, Pat Bucy R, Spritzler J, et al. Evidence that intermittent structured treatment interruption, but not immunization with ALVACHIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J Infect Dis. 2006;194:623-632.
5. Routy JP, Boulassel MR, Yassine-Diab B, et al. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol. 2010;134:140-147.
6. Tcherepanova I, Starr A, Lackford B, et al. The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, R90. PLoS One. 2009;4:e5853.
7. Liszewski MK, Yu JJ, O'Doherty U. Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. Methods. 2009;47:254-260.
8. D'Aquila RT, Bechtel LJ, Videler JA, et al. Maximizing sensitivity and specificity of PCR by pre-amplification heating. Nucleic Acids Res. 1991; 19:3749.
9. DeBenedette MA, Calderhead DM, Ketteringham H, et al. Priming of a novel subset of CD28+ rapidly expanding high-avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells is IL-12 dependent. J Immunol. 2008;181:5296-5305.
10. Gandhi RT, O'Neill D, Bosch RJ, et al. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine. 2009; 27:6088-6094.
11. Lu W, Arraes L, Ferreira W, et al. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med. 2004;10;1359-1365.
12. Routy JP, Angel J, Vezina S, et al. Final analysis of a phase 2 study of an autologous DC immunotherapy (AGS-004) showed positive outcomes in primary endpoint of viral load control, and favorable safety and immunogenicity profile, in subjects undergoing structured treatment interruption of ART (abstract 385). Presented at: 18th Conference on Retroviruses and Opportunistic Infections; February 27-March 2, 2011; Boston, MA.
13. Garca F, Climent N, Guardo AC, et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med. 2013;5:166ra2.
14. Routy JP, Nicolette C. Arcelis AGS-004 dendritic cell-based immunotherapy for HIV infection. Immunotherapy. 2010;2:467-476.